Abstract
Tisagenlecleucel is a chimeric antigen receptor T-cell therapy for B-cell acute lymphoblastic leukaemia and diffuse large B-cell lymphoma, which has achieved reimbursement using OBR schemes in Europe and the US. OBR schemes are becoming popular to manage uncertainty and alleviate the financial burden on healthcare systems when adopting high-cost medicines. This research will compare reimbursement models that have been developed for tisagenlecleucel.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
